Peter Stüve - Search Results

Year	Number of Results
2014	1
2021	1
2022	3
2023	7
2024	1

1

Microglia as a cellular target of diclofenac therapy in Alzheimer's disease.

Stopschinski BE, Weideman RA, McMahan D, Jacob DA, Little BB, Chiang HS, Saez Calveras N, Stuve O. Stopschinski BE, et al. Ther Adv Neurol Disord. 2023 Feb 27;16:17562864231156674. doi: 10.1177/17562864231156674. eCollection 2023. Ther Adv Neurol Disord. 2023. PMID: 36875711 Free PMC article. Review.

2

Extended-interval dosing of natalizumab in NOVA.

Stüve O, Tugemann B. Stüve O, et al. Lancet Neurol. 2023 Mar;22(3):199-200. doi: 10.1016/S1474-4422(23)00032-7. Lancet Neurol. 2023. PMID: 36804084 No abstract available.

3

Editorial: Animal models of multiple sclerosis: can they advance future therapies?

DeSilva TM, Stuve O. DeSilva TM, et al. Front Mol Neurosci. 2023 Jun 13;16:1229625. doi: 10.3389/fnmol.2023.1229625. eCollection 2023. Front Mol Neurosci. 2023. PMID: 37389092 Free PMC article. No abstract available.

4

Distinctive transcriptomic and epigenomic signatures of bone marrow-derived myeloid cells and microglia in CNS autoimmunity.

Manouchehri N, Salinas VH, Hussain RZ, Stüve O. Manouchehri N, et al. Proc Natl Acad Sci U S A. 2023 Feb 7;120(6):e2212696120. doi: 10.1073/pnas.2212696120. Epub 2023 Feb 2. Proc Natl Acad Sci U S A. 2023. PMID: 36730207 Free PMC article.

5

Tau seeding in cases of multiple sclerosis.

LaCroix MS, Mirbaha H, Shang P, Zandee S, Foong C, Prat A, White CL 3rd, Stuve O, Diamond MI. LaCroix MS, et al. Acta Neuropathol Commun. 2022 Oct 11;10(1):146. doi: 10.1186/s40478-022-01444-2. Acta Neuropathol Commun. 2022. PMID: 36221144 Free PMC article.

6

T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy.

Reder AT, Stuve O, Tankou SK, Leist TP. Reder AT, et al. Mult Scler. 2023 May;29(6):648-656. doi: 10.1177/13524585221134216. Epub 2022 Nov 28. Mult Scler. 2023. PMID: 36440826 Free PMC article. Review.

7

The validity of animal models to explore the pathogenic role of the complement system in multiple sclerosis: A review.

Saez-Calveras N, Brewster AL, Stuve O. Saez-Calveras N, et al. Front Mol Neurosci. 2022 Oct 13;15:1017484. doi: 10.3389/fnmol.2022.1017484. eCollection 2022. Front Mol Neurosci. 2022. PMID: 36311030 Free PMC article. Review.

8

Alemtuzumab: the advantages and challenges of a novel therapy in MS.

Menge T, Stüve O, Kieseier BC, Hartung HP. Menge T, et al. Neurology. 2014 Jul 1;83(1):87-97. doi: 10.1212/WNL.0000000000000540. Epub 2014 Jun 11. Neurology. 2014. PMID: 24920854 Review.

9

Perspective: Industry-patient relationships for the promotion of pharmaceutical agents.

Bryarly MA, Rubin MA, Stuve O. Bryarly MA, et al. Ther Adv Neurol Disord. 2023 Oct 31;16:17562864231207560. doi: 10.1177/17562864231207560. eCollection 2023. Ther Adv Neurol Disord. 2023. PMID: 37920862 Free PMC article. No abstract available.

10

A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis.

Airas L, Bermel RA, Chitnis T, Hartung HP, Nakahara J, Stuve O, Williams MJ, Kieseier BC, Wiendl H. Airas L, et al. Ther Adv Neurol Disord. 2024 Apr 17;17:17562864241233041. doi: 10.1177/17562864241233041. eCollection 2024. Ther Adv Neurol Disord. 2024. PMID: 38638671 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

12 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year